Open AccessHydroxychloroquine and Chloroquine in COVID-19
Author(s) -
Bella Mehta,
Carine Moezinia,
Deanna JannatKhah,
Allan Gibofsky,
Haley Tornberg,
Diyu PearceFisher,
Susan M. Goodman,
Jane E. Salmon,
Said A. Ibrahim
Publication year - 2020
Publication title -
journal of clinical rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.615
H-Index - 50
eISSN - 1536-7355
pISSN - 1076-1608
DOI - 10.1097/rhu.0000000000001539
Subject(s) - hydroxychloroquine , medicine , confidence interval , chloroquine , poisson regression , covid-19 , relative risk , outpatient clinic , disease , population , immunology , environmental health , malaria , infectious disease (medical specialty)
With hydroxychloroquine (HCQ) and chloroquine (CQ) emerging as potential therapies for coronavirus disease 2019 (COVID-19), shortages have been reported. We aimed to understand how rheumatologists, one of the most common prescribers of HCQ/CQ, prescribed these medications to manage COVID-19 and to understand if their patients are affected by shortages.